Business
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines
About this update from Ac Immune Sa
[{"type":"text","content":"AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small molecule Morphomers® with SupraAntigen® monoclonal antibodies, forming a new class of drug-candidates to target toxic proteins in CNS morADC demonstrated significant synergies, substantially increasing blood brain barrier penetration and potency to inhibit protein aggregation compared to the antibody or small molecule alone Lausanne, Switzerland, July 31, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today unveiled a novel class of neurodegenerative disease-fighting drug-candidates called morADC (Morphomer® Antibody Drug Conjugate) in an oral presentation at the annual Alzheimer’s Association International Conference (AAIC 2024), taking place from July 28 – August 1, 2024, in Philadelphia, PA. Dr. Madiha Derouazi, Chief Scientific Officer of AC Immune, presented the characterization and in vitro efficacy of morADC for the first time. The talk, entitled “A new class of neurodegenerative disease-fighting drugs: morADC (Morphomer®- Antibody Drug Conjugates)”, showed that: morADC are designed for CNS applications capable of addressing important targets including Abeta, Tau and a-synucleinmorADC enable single or dual-targeting strategies (e.g. an anti-Abeta antibody combined with an anti-Tau small molecule) to deliver combination therapy in a single therapeutic agentsingle-targeting morADC (i.e. antibody and small molecule targeting the same protein) show significant synergistic anti-aggregation effects compared to the parental moleculesdual-targeting morADC (e.g. Abeta/Tau) show significantly enhanced anti-aggregation effects compared to the parental moleculesadditionally, conjugation of brain-penetrant Morphomers with a monoclonal antibody can multiply antibody brain exposure in comparison to the parent antibody alone While in oncology antibody-drug conjugates are designed to selectively kill tumor cells in a targeted manner, AC Immune’s morADC for neurodegenerative diseases combine the high brain penetrance of Morphomer small molecules with the target specificity of monoclonal antibodies, to reduce pathological, aggregating proteins in the central n...